Skip to content

Bartłomiej Pochwat

3 papers in the library · publishing 2016-2022

Papers

Sort Most recent Most cited

New investigational agents for the treatment of major depressive disorder

Expert Opinion on Investigational Drugs August 17, 2022 Bartłomiej Pochwat, A. Krupa, M. Siwek et al.

ABSTRACT Introduction Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness. Ketamine, with its rapid action and long-lasting effects, represents a breakthrough in the modern pharmacotherapy of depression. Areas covered The current review summarizes the latest findings on the mechanism of the antidepressant...

Hyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice.

Frontiers in Molecular Neuroscience 2018 Bartłomiej Pochwat, Bernadeta Szewczyk, Katarzyna Kotarska et al.

N-methyl-D-aspartate receptor (NMDAR) modulators induce rapid and sustained antidepressant like-activity in rodents through a molecular mechanism of action that involves the activation of Ca2+ dependent signaling pathways. Moreover, ketamine, a global NMDAR antagonist is a potent, novel, and atypical drug that has been successfully used to treat major depressive disorder (MDD). However, because...

Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats

Psychopharmacology June 11, 2016 K. Podkowa, Bartłomiej Pochwat, P. Brański et al.

Numerous preclinical and clinical studies have reported the rapid and sustained antidepressant effects of the NMDA receptor antagonist ketamine. Because ketamine induces several undesirable and dangerous effects, a variety of strategies have been suggested to avoid such effects. Here, we propose to enhance the sub-effective doses of ketamine by co-administration with the group II metabotropic...